首页> 外文OA文献 >Correction: Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

【2h】

Correction: Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

机译：校正：评估血浆Lyso-GB3用于临床监测Migalastat治疗患者的临床监测治疗患者的法布里病

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Daniel G. Bichet; Johannes M. Aerts; Christiane Auray-Blais; Hiroki Maruyama; Atul B. Mehta; Nina Skuban; Eva Krusinska; Raphael Schiffmann;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pegunigalsidase alfa, PEGylated a-galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal GB3 inclusion clearance and reduction of plasma Lyso-GB3 [J] . Molecular genetics and metabolism . 2020,第2期

机译：Pegunigalsidase Alfa，Pegymated A-半乳糖苷酶 - 一种用于治疗法布里疾病的开发中，显示出肾GB3夹杂物间隙与血浆LySO-GB3的减少之间的相关性
2. Plasma lyso-Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes [J] . Nowak Albina, Mechtler Thomas P., Desnick Robert J., Molecular genetics and metabolism . 2017,第1a2期

机译：血浆Lyso-GB3：一种有用的生物标志物，用于诊断和治疗法布里病杂合子
3. Plasma lyso-Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes [J] . Nowak Albina, Mechtler Thomas P., Desnick Robert J., Molecular genetics and metabolism . 2017,第1a2期

机译：血浆Lyso-GB3：一种有用的生物标志物，用于诊断和治疗法布里病杂合子
4. Accurate Quantitation of Plasma Globotriaosylsphingosine (lyso-Gb3) in Healthy Individuals and Fabry Patients by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) [C] . Rick Hamler, Nastry Brignol, Robert E. Boyd, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：通过液相色谱 - 串联质谱法（LC-MS / MS）精确定量健康个体和法布里患者的血浆球蛋白血糖素（LySO-GB3）
5. The impact of telemonitoring on self -efficacy, emotional well -being, and clinical outcomes in patients with chronic obstructive pulmonary disease or heart failure [D] . West-Frasier, Jaclyn 2008

机译：远程监护对慢性阻塞性肺疾病或心力衰竭患者自我效能，情绪健康和临床结局的影响
6. Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients [O] . Brandy Young-Gqamana, Nastry Brignol, Hui-Hwa Chang, -1

机译：米加司他HCl的法布里转基因小鼠和在法布里患者血浆减少Globotriaosylsphingosine（溶血Gb3的）
7. Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis [O] . Hiroki Maruyama, Kaori Miyata, Mariko Mikame, 2019

机译：校正：血浆LySO-GB3作为生物标志物的疗效，用于从多特异性诊所选择高危患者的生物标志物进行遗传分析
8. Myeloid Bodies in Patients without Clinical Fabry's Disease [R] . McNamara, T. E., Butkus, D. E., Goodloe, S. 1978

机译：没有临床法布里病的患者的骨髓体

Correction: Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

著录项

引文网络

相似文献

相关主题

期刊订阅